Stanozol 20 mg (Winstrol) is a reference compound used in androgen-receptor and metabolic research models. It is structurally derived from dihydrotestosterone (DHT) and is studied for its ability to support lean tissue maintenance, SHBG regulation, and anabolic-to-androgenic selectivity. EU Pharmaceuticals supplies Stanozol 20 mg tablets for controlled laboratory and educational analysis of anabolic signaling pathways.

Key Research Features

• Compound: Stanozolol (Winstrol)
• Class: Synthetic anabolic reference steroid
• Primary focus: SHBG modulation and lean-tissue metabolism studies
• Half-life (oral): ~9 hours

Research Overview

Stanozolol has been widely studied for its binding affinity to androgen receptors and potential to alter sex hormone-binding globulin (SHBG) levels. By reducing SHBG, a greater fraction of circulating androgens remain unbound, allowing researchers to evaluate free-testosterone dynamics in metabolic and muscular models. It is also frequently used in studies of protein synthesis, nitrogen retention, and lean-mass maintenance under caloric deficit conditions.

Product Specifications

• Form: Oral tablets
• Strength: 20 mg Stanozolol per tablet
• Quantity: 56 tablets per pack

Reference Sampling Protocol (Educational)

Reference Notes & Handling

• Upper limit: Do not exceed 20 mg per dose or 60 mg in 24 hours within reference settings.
• Sampling schedule: Due to its 9-hour half-life, spacing doses every 8–12 hours is optimal for steady plasma reference levels.
• SHBG study dose: ~0.2 mg/kg body weight per day used in published models for SHBG suppression analysis.
• Oral administration: Take with food to minimize gastric irritation (avoid fatty meals 1 hour before sampling).
• Hydration: Adequate water intake recommended to limit renal stress during sampling periods.

Observation Cycle

• Minimum duration: 4 weeks (typical cutting models)
• Extended duration: 6 – 8 weeks commonly used in SHBG and lean-mass maintenance protocols
• Reported extended range: Up to 12 weeks in long-term observation with adequate monitoring

Observed Outcomes (Research Reference)

• Reduction in SHBG levels leading to higher measurable free-testosterone fractions.
• Enhanced protein synthesis and lean-mass preservation during caloric restriction.
• Increased muscle density and vascular definition in comparative studies.
• Minimal aromatization or estrogenic conversion.

Data reflect controlled laboratory conditions and are not intended for therapeutic guidance.

Potential Side Observations

• Transient joint stiffness or dryness at high cumulative exposure.
• May elevate liver enzymes in prolonged studies — monitor where appropriate.
• Symptoms generally resolve upon discontinuation or dose reduction.

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals manufactures reference compounds verified through HPLC and MS testing for purity and consistency. Each batch is analytically certified to support accurate and repeatable research outcomes in anabolic androgen modelling.

For laboratory, educational, and research use only. Not for human or veterinary ingestion or therapeutic application. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and regulatory compliance.